Abera Bioscience AB (NGM:ABERA)

Market Cap	106.70M
Revenue (ttm)	14.85M
Net Income (ttm)	-1.10M
Shares Out	15.35M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,399
Average Volume	11,887
Open	6.95
Previous Close	6.70
Day's Range	6.35 - 6.95
52-Week Range	3.51 - 6.70
Beta	1.00
RSI	66.81
Earnings Date	May 13, 2025

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 6
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ABERA

Financial Performance

In 2024, Abera Bioscience AB's revenue was 14.85 million, an increase of 488.13% compared to the previous year's 2.52 million. Losses were -1.10 million, -93.42% less than in 2023.